A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design
Abstract
Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease requiring kidney transplantation and can recur in the allograft in 30-80% of recipients resulting in reduced graft survival. Plasmapheresis has shown efficacy in treating some cases of recurrent FSGS but isolated plasmapheresis has not demonstrated efficacy in preventing recurrent FSGS. Rituximab has had anecdotal success in preventing recurrence in a single center study but has not been studied in combination with plasmapheresis for preventing FSGS recurrence.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 15, 2023
- Source ID
- 10.3389/fneph.2023.1181076
Entities
People
- Ajay K. Israni
- Amit Govil
- Blanche Chavers
- Christie P. Thomas
- David K. Hooper
- Eileen Tsai Chambers
- Hatem Amer
- Jodi Smith
- Junichiro Sageshima
- Lyndsay Harshman
- Margret Bock
- Michael Seifert
- Michelle N. Rheault
- Mireile El Ters
- Priya S. Verghese
- Qi Wang
- Randall Sung
- Rasheed Gbadegesin
- Ron Shapiro
- Rouba Garro
- Samy Riad
- Sandra Amaral
Organizations
- Congressionally Directed Medical Research Programs